Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BRIGHTSTAR: A Pilot Trial of Local Consolidative Therapy (LCT) With Brigatinib in Tyrosine Kinase Inhibitor-Naive ALK-Rearranged Advanced NSCLC

NCT03707938 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03707938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03707938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BRIGHTSTAR: A Pilot Trial of Local Consolidative Therapy (LCT) With Brigatinib in Tyrosine Kinase Inhibitor-Naive ALK-Rearranged Advanced NSCLC
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 18, 2018
Completion date
January 28, 2026
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung carcinoma, alk gene rearrangement, lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, stage iv lung cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8